Abstract
HER-2/neu transgene-modified dendritic cell (DC)-based vaccines are potent at eliciting HER-2/neu-specific antitumor immunity. In this study, we constructed a recombinant adenovirus RGDAdVneu with fiber gene modified by RGD insertion into the viral knob's H1 loop. We transfected DCs with RGDAdVneu, and assessed/compared HER-2/neu-specific humoral and cytotoxic T lymphocyte (CTL) responses and antitumor immunity derived from the original AdVneu-transfected DCs (DCneu1) and RGDAdVneu-transfected DCs (DCneu2). We demonstrated that DCneu2 displayed increased HER-2/neu expression by 8.3-fold compared to DCneu1. We also demonstrated that DCneu2 vaccination induced stronger HER-2/neu-specific humoral and CTL immune responses than DCneu1 vaccination. DCneu2 vaccination protected all the mice from HER-2/neu-expressing Tg1-1 tumor cell challenge in wild-type FVB/NJ mice, compared to a partial protection in DCneu1-immunized mice. In addition, DCneu2 vaccination also significantly delayed tumor growth than DCneu1 immunization (P<0.05) in Tg FVBneuN mice. Three immunizations of DCneu2 starting at the mouse age of 2 months also significantly delayed breast cancer development in Tg mice compared to DCneu2 vaccine (P<0.05). Importantly, DCneu2 vaccine reduced breast carcinogenesis by 9% in Tg mice with self HER-2/neu tolerance. Therefore, vaccination of fiber-modified adenovirus-transfected DCs to enhance expression of tumor antigens such as HER-2/neu is likely representative of a new direction in DC-based vaccine of breast cancer.
Similar content being viewed by others
References
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712.
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16: 1340–1349.
Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA . High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 3363–3367.
Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16–20.
Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ . Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92: 432–436.
Schuler G, Koch F, Heufler C, Kampgen E, Topar G, Romani N . Murine epidermal Langerhans cells as a model to study tissue dendritic cells. Adv Exp Med Biol 1993; 329: 243–249.
Banchereau J, Steinman RM . Dendritic cells and the control of immunity. Nature 1998; 392: 245–252.
Thery C, Amigorena S . The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 2001; 13: 45–51.
Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451–6458.
Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002; 99: 2845–2850.
Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, Schmitt M et al. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 2002; 99: 3717–3724.
Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP . Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996; 170: 111–119.
Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–1526.
Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336–1343.
Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003; 170: 4273–4280.
Nelson CA, Petzold SJ, Unanue ER . Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell. Nature 1994; 371: 250–252.
Levitsky V, Zhang QJ, Levitskaya J, Masucci MG . The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein–Barr virus nuclear antigen 4. J Exp Med 1996; 183: 915–926.
Lipford GB, Bauer S, Wagner H, Heeg K . In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine 1995; 13: 313–320.
Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF . Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28: 496–504.
Pellegatta S, Poliani PL, Corno D, Grisoli M, Cusimano M, Ubiali F et al. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 2006; 28: 527–531.
Fallarino F, Grohmann U, Bianchi R, Vacca C, Fioretti MC, Puccetti P . Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol 2000; 165: 5495–5501.
Chen Y, Emtage P, Zhu Q, Foley R, Muller W, Hitt M et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Therapy 2001; 8: 316–323.
Chen Z, Huang H, Chang T, Carlsen S, Saxena A, Marr R et al. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Ther 2002; 9: 778–786.
zum Buschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H . The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol 2001; 167: 1712–1719.
Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67: 1842–1852.
Dees EC, McKinnon KP, Kuhns JJ, Chwastiak KA, Sparks S, Myers M et al. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother 2004; 53: 777–785.
Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 2004; 64: 8022–8028.
Chan T, Sami A, El-Gayed A, Guo X, Xiang J . HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Therapy 2006; 13: 1391–1402.
Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ . DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998; 58: 1965–1971.
Wright P, Braun R, Babiuk L, Littel-van den Hurk SD, Moyana T, Zheng C et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999; 14: 49–57.
Okada N, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Saito T et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun 2001; 282: 173–179.
Okada N, Masunaga Y, Okada Y, Iiyama S, Mori N, Tsuda T et al. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther 2003; 10: 421–431.
Campbell M, Qu S, Wells S, Sugandha H, Jensen RA . An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression. Cancer Gene Ther 2003; 10: 559–570.
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509–2514.
Liu Y, Ye T, Sun D, Maynard J, Deisseroth A . Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum Gene Ther 2004; 15: 637–647.
Zeng M, Smith SK, Siegel F, Shi Z, Van Kampen KR, Elmets CA et al. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 2001; 31: 260–262.
Xiang J, Qi Y, Cook D, Moyana T . Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Hum Antibodies Hybridomas 1996; 7: 2–10.
Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96: 878–884.
Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201: 1591–1602.
Xiang J, Huang H, Liu Y . A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 2005; 174: 7497–7505.
Liu Y, Xia D, Li F, Zheng C, Xiang J . Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 2005; 12: 122–132.
Xiang J, Moyana T . Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. J Interferon Cytokine Res 2000; 20: 349–354.
Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP . Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 5260–5266.
Dyer MR, Herrling PL . Progress and potential for gene-based medicines. Mol Ther 2000; 1: 213–224.
Marshall E . Gene therapy. Second child in French trial is found to have leukemia. Science 2003; 299: 320.
Graham FL . Adenovirus vectors for high-efficiency gene transfer into mammalian cells. Immunol Today 2000; 21: 426–428.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309–319.
Nemerow GR . Cell receptors involved in adenovirus entry. Virology 2000; 274: 1–4.
Huang S, Endo RI, Nemerow GR . Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995; 69: 2257–2263.
Huang S, Kamata T, Takada Y, Ruggeri ZM, Nemerow GR . Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 1996; 70: 4502–4508.
Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61: 7913–7919.
Dietz AB, Bulur PA, Brown CA, Pankratz VS, Vuk-Pavlovic S . Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression. Gene Therapy 2001; 8: 419–423.
Pasare C, Medzhitov R . Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299: 1033–1036.
Silva RA, Pais TF, Appelberg R . Evaluation of IL-12 in immunotherapy and vaccine design in experimental Mycobacterium avium infections. J Immunol 1998; 161: 5578–5585.
Uekusa Y, Gao P, Yamaguchi N, Tomura M, Mukai T, Nakajima C et al. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses. J Leukoc Biol 2002; 72: 864–873.
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61: 4892–4900.
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ . Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992; 89: 10578–10582.
Cifaldi L, Quaglino E, Di Carlo E, Musiani P, Spadaro M, Lollini PL et al. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 2001; 61: 2809–2812.
Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000; 60: 3569–3576.
Pupa SM, Invernizzi AM, Forti S, Di Carlo E, Musiani P, Nanni P et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Therapy 2001; 8: 75–79.
Takeuchi N, Hiraoka S, Zhou XY, Nagafuku M, Ono S, Tsujimura T et al. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice. Cancer Res 2004; 64: 7588–7595.
Acknowledgements
This study was supported by research grants of Canadian Institutes of Health Research ((MOP 81228), Canadian Breast Cancer Foundation (G9519) and Saskatchewan Cancer Agency (5-753).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sas, S., Chan, T., Sami, A. et al. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice. Cancer Gene Ther 15, 655–666 (2008). https://doi.org/10.1038/cgt.2008.18
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2008.18
- Springer Nature America, Inc.
Keywords
This article is cited by
-
Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses
Cancer Gene Therapy (2013)
-
Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice
Breast Cancer Research and Treatment (2013)
-
Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
Cancer Gene Therapy (2011)
-
A Distinct Role of CD4+ Th17- and Th17-Stimulated CD8+ CTL in the Pathogenesis of Type 1 Diabetes and Experimental Autoimmune Encephalomyelitis
Journal of Clinical Immunology (2011)
-
Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity
Cancer Immunology, Immunotherapy (2011)